


PHARMACEUTICAL 2019

ALPINE IMMUNE SCIENCES INC. Rank 151 of 363









PHARMACEUTICAL 2019



ALPINE IMMUNE SCIENCES INC. Rank 151 of 363

The relative strengths and weaknesses of ALPINE IMMUNE SCIENCES INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ALPINE IMMUNE SCIENCES INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 98% points. The greatest weakness of ALPINE IMMUNE SCIENCES INC. is the variable Research and Development, reducing the Economic Capital Ratio by 46% points.

The company's Economic Capital Ratio, given in the ranking table, is 123%, being 87% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	53,545
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,127
Liabilities, Non-Current	2,155
Other Assets	132
Other Compr. Net Income	46
Other Expenses	1,156
Other Liabilities	0
Other Net Income	0
Other Revenues	2,001
Property and Equipment	1,196
Research and Development	28,970
Selling, General and Administrative Expense	8,362

Output Variable	Value in 1000 USD
Assets	54,873
Liabilities	10,282
Expenses	38,488
Revenues	2,001
Stockholders Equity	44,591
Net Income	-36,487
Comprehensive Net Income	-36,464
Economic Capital Ratio	123%

